Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CDNA - CareDx, Inc.
Market Cap 605.71M P/E - EPS this Y 17.20% Ern Qtrly Grth -
Income -190.28M Forward P/E -15.86 EPS next Y 13.20% 50D Avg Chg 24.00%
Sales 280.32M PEG -0.76 EPS past 5Y - 200D Avg Chg -3.00%
Dividend N/A Price/Book 1.44 EPS next 5Y 20.00% 52W High Chg -59.00%
Recommedations 2.10 Quick Ratio 3.67 Shares Outstanding 51.78M 52W Low Chg 81.00%
Insider Own 3.75% ROA -12.88% Shares Float 50.64M Beta 1.45
Inst Own 97.03% ROE -54.98% Shares Shorted/Prior 4.69M/4.36M Price 11.26
Gross Margin 63.61% Profit Margin -67.88% Avg. Volume 925,998 Target Price 12.40
Oper. Margin -37.91% Earnings Date May 8 Volume 1,503,029 Change 7.34%
Healthcare | Diagnostics & Research | United States
About CareDx, Inc.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CareDx, Inc. News
04/19/24 CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
04/18/24 CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
04/16/24 CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
04/09/24 CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
04/01/24 How CareDx (CDNA) Stock Stands Out in a Strong Industry
03/11/24 CareDx Appoints Bryan Riggsbee to Its Board of Directors
03/01/24 CareDx Full Year 2023 Earnings: EPS Misses Expectations
02/29/24 CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript
02/29/24 Q4 2023 CareDx Inc Earnings Call
02/28/24 CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
02/28/24 CareDx Inc (CDNA) Surpasses Revenue Expectations Despite Net Loss Expansion in 2023
02/28/24 CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
02/27/24 CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference
09:15 AM Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics
02/21/24 CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
02/21/24 CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
09:45 PM CareDx Issues Statement in Patent Infringement Case
01/22/24 CareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 16% this week, taking three-year losses to 89%
01/11/24 CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
01/09/24 CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
CDNA Chatroom

User Image Stock_Titan Posted - 6 days ago

$CDNA CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/CDNA/care-dx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-dgex84y98pgw.html

User Image Doozio Posted - 2 weeks ago

$CDNA 🧠⏰🎁 area. “Allegedly “

User Image Stock_Titan Posted - 2 weeks ago

$CDNA CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting https://www.stocktitan.net/news/CDNA/care-dx-and-collaborators-present-latest-cardiothoracic-advancements-0jlaah388cg1.html

User Image Doozio Posted - 3 weeks ago

$CDNA chop chop huckleberries n 🎁 area in 🧠⏰. 2021 highs around 100?

User Image jaydilks Posted - 03/27/24

$ARKG Leaders of ARKG today. $NRIX $CDNA $QSI

User Image Aigner_Andreas Posted - 1 month ago

TD BUY $CDNA at 9.85, Supp 9.85 Resis 12.08 R23 HiLo 62% T1Y 40 buy 1.6 DIV N/A #Caredx Inc #stocks #trading #finance #market

User Image ValentinaZevallos1 Posted - 1 month ago

$CDNA Nobody should be loosing money in this stock market at all! Our January was amazing and our February was even better! Here was our February results, remember guys, don’t chase! We got in BMR and HOLO early before they ran over 1000% - onto the next one!

User Image _StockTrader Posted - 1 month ago

Real-Time Stock Data $CDNA Price: 12.31 Volume: 1006372 Market Cap: 667033280 PE Ratio: -34.25 Stock data provided by: AITX

User Image jhof Posted - 1 month ago

$CDNA Picking up steam. Let's go over 13!

User Image Chilantaent Posted - 1 month ago

$CDNA Where are we heading too

User Image jaydilks Posted - 1 month ago

$ARKG Leaders today. $CDNA

User Image _www_larval_com_ Posted - 02/29/24

$CDNA just turned -3% lower to 8% (~2Mv) a moment ago, 03/15 options, follow for more volatility.

User Image Me0wth Posted - 02/29/24

$CDNA crazy recovery 😺💰

User Image DonCorleone77 Posted - 02/28/24

$CDNA CareDx sees FY24 revenue $260M-$274M, consensus $260.6M

User Image DonCorleone77 Posted - 02/28/24

$CDNA CareDx reports Q4 EPS (17c), consensus (27c) Reports Q4 revenue $65.6M, consensus $63.7M. "In 2023, we met our challenges head-on as we navigated the impact of Medicare coverage changes. We reset our operations, strategically reduced our cost structure, and created a growth pathway for the company in the second half of the year, as we continued to focus on care for transplant patients," said Alex Johnson, President of Patient and Testing Services, and a member of the Office of the CEO at CareDx. "Looking forward to 2024, we are focused on delivering high-value clinical and digital solutions to improve allograft survival, while generating evidence for expanding payer coverage and accelerating our path back to profitability."

User Image epsguid Posted - 02/28/24

$CDNA reported a loss of $2.21, consensus was ($0.46) via @eWhispers #epsmiss http://eps.sh/d/cdna

User Image Stock_Titan Posted - 02/28/24

$CDNA CareDx Announces Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/CDNA/care-dx-announces-fourth-quarter-and-full-year-2023-financial-qas72996nxrp.html

User Image Stock_Titan Posted - 02/27/24

$CDNA CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference https://www.stocktitan.net/news/CDNA/care-dx-to-participate-in-the-raymond-james-amp-associates-45th-xknpork0ha98.html

User Image briefingcom Posted - 02/27/24

$NTRA: Natera announced the next phase of proceedings in its patent infringement litigation against CareDx $CDNA https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240227081229NTRA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image DonCorleone77 Posted - 02/27/24

$NTRA $CDNA Natera announces next phase of CareDx patent infringement litigation Natera (NTRA) announced the next phase of proceedings in its patent infringement litigation against CareDx (CDNA). The U.S. District Court for the District of Delaware will now determine if CareDx owes a royalty for future infringement related to ongoing and future AlloSure testing occurring after August 2023. This follows a Jan. 2024 jury verdict in favor of Natera, in which the jury awarded $96.3M in damages to Natera in lost profits and past royalties through August 2023. The jury found that CareDx's AlloSure and AlloSeq tests infringed one of the two Natera patents asserted against CareDx and that all asserted claims of both patents are valid on various grounds. Discovery and briefing for this next phase are expected to last through the end of summer 2024.

User Image eWhispers Posted - 2 months ago

volatility anyone? http://eps.sh/wrs $PAYO $EHTH $AGL $CDNA $PCT

User Image Me0wth Posted - 2 months ago

$CDNA all in at 5.40 😹💰

User Image mcrotary Posted - 2 months ago

User Image Stock_Titan Posted - 2 months ago

$CDNA CareDx to Report Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/CDNA/care-dx-to-report-fourth-quarter-and-full-year-2023-financial-0u2y9jjq350s.html

User Image Stock_Titan Posted - 2 months ago

$CDNA CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings https://www.stocktitan.net/news/CDNA/care-dx-showcases-digital-solutions-and-pipeline-in-cellular-4f1xjfb8513r.html

User Image Me0wth Posted - 2 months ago

$CDNA not bad 😺💰

User Image Wei2hot Posted - 2 months ago

$CDNA no volume on robinhood?

User Image Me0wth Posted - 2 months ago

$CDNA in for 20,000 shares at 5 dollars 😺💰

User Image jiggs10 Posted - 2 months ago

$CDNA This one is toasted

User Image RocketThief Posted - 01/31/24

$CDNA even with the damages from the court case, EV is barely above 1x sales. There isn’t any impact that I can discern on the business itself. Great time to accumulate if you like the biz model

Analyst Ratings
Stephens & Co. Overweight Apr 17, 24
Stephens & Co. Overweight Nov 9, 23
Stephens & Co. Equal-Weight Sep 26, 23
Raymond James Outperform Aug 15, 23
HC Wainwright & Co. Neutral Aug 9, 23
Raymond James Market Perform Jul 11, 23
BTIG Neutral May 11, 23
Stephens & Co. Equal-Weight Mar 7, 23
Goldman Sachs Buy Mar 7, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Seeto Reginald See Remarks See Remarks Oct 02 Sell 6.9139 2,818 19,483 479,164 10/02/23
Seeto Reginald See Remarks See Remarks Aug 14 Sell 8.8935 576 5,123 484,801 08/14/23
Bickerstaff George Director Director Aug 11 Option 5.15 19,453 100,183 99,721 08/11/23
Seeto Reginald See Remarks See Remarks Aug 02 Sell 10.97 2,819 30,924 486,051 08/02/23
Seeto Reginald See Remarks See Remarks Jul 13 Sell 10.3341 5,260 54,357 488,870 07/13/23
Maag Peter Director Director Jul 13 Sell 10.3361 5,000 51,680 309,657 07/13/23
Seeto Reginald See Remarks See Remarks Jul 03 Sell 8.4815 2,818 23,901 498,055 07/03/23
Seeto Reginald See Remarks See Remarks Jun 28 Sell 8.762 14,268 125,016 500,873 06/28/23
Maag Peter Director Director Jun 28 Sell 8.7235 2,432 21,216 313,136 06/28/23
Seeto Reginald See Remarks See Remarks Jun 02 Sell 8.1275 2,819 22,911 532,177 06/02/23
Seeto Reginald See Remarks See Remarks May 02 Sell 8.1227 2,819 22,898 534,996 05/04/23
Seeto Reginald See Remarks See Remarks Apr 03 Sell 8.9514 2,818 25,225 537,815 04/03/23
Seeto Reginald See Remarks See Remarks Mar 02 Sell 15.8772 2,819 44,758 540,633 03/06/23
Seeto Reginald See Remarks See Remarks Feb 09 Sell 15.8 19,582 309,396 543,452 02/13/23
Seeto Reginald See Remarks See Remarks Feb 07 Sell 16.4019 3,069 50,337 563,034 02/08/23
Maag Peter Director Director Feb 08 Sell 15.7543 3,269 51,501 295,468 02/08/23
Seeto Reginald See Remarks See Remarks Feb 01 Sell 17.29 2,819 48,741 575,803 02/03/23
Maag Peter Director Director Feb 01 Sell 17.17 5,000 85,850 298,737 02/03/23
Seeto Reginald See Remarks See Remarks Jan 03 Sell 11.6877 2,818 32,936 268,906 01/03/23
Bickerstaff George Director Director Nov 23 Option 1.22 15,000 18,300 60,101 11/23/22
Colon Grace Director Director Aug 10 Sell 24.81 2,521 62,546 4,864 08/11/22
Maag Peter Director Director Aug 11 Sell 24.98 20,000 499,600 297,039 08/11/22
Colon Grace Director Director May 11 Sell 23.01 5,179 119,169 2,522 05/13/22
Goldberg Michael Director Director Apr 11 Option 1.22 500 610 62,767 04/13/22
Goldberg Michael Director Director Apr 11 Sell 36.01 500 18,005 62,267 04/13/22
Maag Peter Director Director Apr 05 Option 21.25 9,950 211,438 321,689 04/06/22
Maag Peter Director Director Apr 05 Sell 38.91 10,000 389,100 311,689 04/06/22
Seeto Reginald See Remarks See Remarks Mar 21 Sell 40.4343 2,888 116,774 187,282 03/23/22
Goldberg Michael Director Director Mar 09 Option 1.22 500 610 61,767 03/11/22
Goldberg Michael Director Director Mar 09 Sell 33.41 500 16,705 61,267 03/11/22
Colon Grace Director Director Mar 09 Sell 34.5629 1,393 48,146 7,701 03/11/22
Maag Peter Director Director Mar 07 Option 18.3 4,056 74,225 321,739 03/08/22
Maag Peter Director Director Mar 07 Sell 33.2 10,000 332,000 311,739 03/08/22
Seeto Reginald See Remarks See Remarks Feb 28 Sell 38.62 3,153 121,769 190,170 03/01/22
Bickerstaff George Director Director Feb 28 Sell 39.1069 25,000 977,673 37,736 03/01/22
Seeto Reginald See Remarks See Remarks Feb 09 Sell 45.0035 2,550 114,759 190,170 02/10/22
Goldberg Michael Director Director Feb 09 Option 1.22 500 610 61,767 02/10/22
Goldberg Michael Director Director Feb 09 Sell 42.96 500 21,480 61,267 02/10/22
Maag Peter Director Director Feb 07 Sell 42.06 10,000 420,600 317,683 02/08/22
Seeto Reginald See Remarks See Remarks Feb 02 Sell 40.8 8,170 333,336 192,720 02/04/22
Seeto Reginald See Remarks See Remarks Jan 29 Sell 42.13 814 34,294 129,928 02/03/22
Goldberg Michael Director Director Jan 10 Option 1.22 500 610 61,767 01/11/22
Goldberg Michael Director Director Jan 10 Sell 42.97 500 21,485 61,267 01/11/22
Goldberg Michael Director Director Dec 09 Option 1.22 500 610 61,068 12/13/21
Goldberg Michael Director Director Dec 09 Sell 45.41 500 22,705 60,568 12/13/21
Goldberg Michael Director Director Nov 09 Option 1.22 500 610 61,068 11/10/21
Goldberg Michael Director Director Nov 09 Sell 47.54 500 23,770 60,568 11/10/21
Goldberg Michael Director Director Oct 11 Option 1.22 500 610 61,068 10/12/21
Goldberg Michael Director Director Oct 11 Sell 62.5 500 31,250 60,568 10/12/21
Maag Peter Executive Chair Executive Chair Sep 07 Sell 74.4 10,000 744,000 341,756 09/07/21